Jazz Pharmaceuticals advertising spend, FY2025

Jazz Pharmaceuticals (JAZZ) reported $106M of advertising expense for the fiscal year ended Dec 31, 2025. That is 2.5% of revenue of $4.3B. Down 1.7% from FY2024.

Ad spend, FY2025
$106M
year ended Dec 31, 2025
Change vs prior year
-1.7%
vs FY2024
Share of revenue
2.5%
of $4.3B revenue
Rank by ad spend
#330
of 458 companies

Key facts

  • Ad spend is 3.8x its FY2015 level ($27.9M), faster than revenue (3.2x).
  • The highest year on file is FY2021 at $162M; FY2025 is 35% below it.
  • Largest increase +2470.0% in FY2014; largest cut -37.5% in FY2011.
  • Ad spend is 2.5% of revenue, down from 4.2% in FY2020.
  • Jazz Pharmaceuticals spends more on advertising than 28% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is below the median of 4.5%.

Ad spend by fiscal year

$0 $50M $100M $150M $200M FY2009 (ended 2009-12-31): $400K FY2010 (ended 2010-12-31): $1.6M 2010 FY2011 (ended 2011-12-31): $1M FY2012 (ended 2012-12-31): $700K FY2013 (ended 2013-12-31): $1M 2013 FY2014 (ended 2014-12-31): $25.7M FY2015 (ended 2015-12-31): $27.9M FY2016 (ended 2016-12-31): $29.5M 2016 FY2017 (ended 2017-12-31): $36.6M FY2018 (ended 2018-12-31): $37.4M FY2019 (ended 2019-12-31): $65.4M 2019 FY2020 (ended 2020-12-31): $99.6M FY2021 (ended 2021-12-31): $162M FY2022 (ended 2022-12-31): $109M 2022 FY2023 (ended 2023-12-31): $92.2M FY2024 (ended 2024-12-31): $107M FY2025 (ended 2025-12-31): $106M 2025 $106M

Ad spend as % of revenue

0% 2% 4% 6% FY2009 (ended 2009-12-31): 0.3% FY2010 (ended 2010-12-31): 0.9% 2010 FY2011 (ended 2011-12-31): 0.4% FY2012 (ended 2012-12-31): 0.1% FY2013 (ended 2013-12-31): 0.1% 2013 FY2014 (ended 2014-12-31): 2.2% FY2015 (ended 2015-12-31): 2.1% FY2016 (ended 2016-12-31): 2.0% 2016 FY2017 (ended 2017-12-31): 2.3% FY2018 (ended 2018-12-31): 2.0% FY2019 (ended 2019-12-31): 3.0% 2019 FY2020 (ended 2020-12-31): 4.2% FY2021 (ended 2021-12-31): 5.2% FY2022 (ended 2022-12-31): 3.0% 2022 FY2023 (ended 2023-12-31): 2.4% FY2024 (ended 2024-12-31): 2.6% FY2025 (ended 2025-12-31): 2.5% 2025 2.5%

Ad spend in context, FY2025

Advertising was 5.8% of selling, general and administrative expense. Research and development spending was 7.4x advertising. The company reported an operating loss of $430M.

Advertising $106M AdvertisingExpense
Selling, general and administrative $1.8B ad spend = 5.8%
Research and development $783M R&D = 7.4x ad spend
Operating loss -$430M
Net loss -$356M

Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.

History

Download CSV
Fiscal year Period end Ad spend YoY Revenue Ad / revenue Tag Filing
FY2025 Dec 31, 2025 $106M -1.7% $4.3B 2.5% AdvertisingExpense 10-K Feb 24, 2026
FY2024 Dec 31, 2024 $107M +16.5% $4.1B 2.6% AdvertisingExpense 10-K Feb 24, 2026
FY2023 Dec 31, 2023 $92.2M -15.3% $3.8B 2.4% AdvertisingExpense 10-K Feb 24, 2026
FY2022 Dec 31, 2022 $109M -32.6% $3.7B 3.0% AdvertisingExpense 10-K Feb 26, 2025
FY2021 Dec 31, 2021 $162M +62.1% $3.1B 5.2% AdvertisingExpense 10-K Feb 28, 2024
FY2020 Dec 31, 2020 $99.6M +52.3% $2.4B 4.2% AdvertisingExpense 10-K Mar 1, 2023
FY2019 Dec 31, 2019 $65.4M +74.9% $2.2B 3.0% AdvertisingExpense 10-K Mar 1, 2022
FY2018 Dec 31, 2018 $37.4M +2.2% $1.9B 2.0% AdvertisingExpense 10-K Feb 23, 2021
FY2017 Dec 31, 2017 $36.6M +24.1% $1.6B 2.3% AdvertisingExpense 10-K Feb 25, 2020
FY2016 Dec 31, 2016 $29.5M +5.7% $1.5B 2.0% AdvertisingExpense 10-K Feb 26, 2019
FY2015 Dec 31, 2015 $27.9M +8.6% $1.3B 2.1% AdvertisingExpense 10-K Feb 27, 2018
FY2014 Dec 31, 2014 $25.7M +2470.0% $1.2B 2.2% AdvertisingExpense 10-K Feb 28, 2017
FY2013 Dec 31, 2013 $1M +42.9% $872M 0.1% AdvertisingExpense 10-K Feb 23, 2016
FY2012 Dec 31, 2012 $700K -30.0% $586M 0.1% AdvertisingExpense 10-K Feb 24, 2015
FY2011 Dec 31, 2011 $1M -37.5% $272M 0.4% AdvertisingExpense 10-K Feb 25, 2014
FY2010 Dec 31, 2010 $1.6M +300.0% $174M 0.9% AdvertisingExpense 10-K Feb 26, 2013
FY2009 Dec 31, 2009 $400K n/a $128M 0.3% AdvertisingExpense 10-K Feb 28, 2012

Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.

What the figure is

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Compared with similar spenders

The 6 companies closest to Jazz Pharmaceuticals in latest-year ad spend.

Rank Company Ad spend Ad / revenue YoY Fiscal year
326 T. Rowe Price $107M 1.5% -17.1% FY2025
327 Coursera $107M 14.1% +70.7% FY2025
328 RH $106M 3.1% -13.1% FY2026
329 Brilliant Earth Group $106M 24.2% -2.2% FY2025
330 Jazz Pharmaceuticals $106M 2.5% -1.7% FY2025
331 BGC Group $105M 3.6% +49.3% FY2025
332 Oxford Industries $104M 7.0% -6.3% FY2026

Full ranking of 458 companies · Biggest cuts #116 · Ads above operating profit #117

Questions

How much does Jazz Pharmaceuticals spend on advertising?

Jazz Pharmaceuticals spent $106M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 24, 2026.

What percentage of revenue does Jazz Pharmaceuticals spend on advertising?

2.5% of revenue in fiscal 2025 ($106M against $4.3B). The median across the 458 companies tracked is 4.5%.

Is Jazz Pharmaceuticals spending more on advertising?

No. Ad spend fell 1.7% in fiscal 2025 from fiscal 2024.

How does Jazz Pharmaceuticals rank by advertising spend?

#330 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.

Does Jazz Pharmaceuticals spend more on advertising than on R&D?

No. In fiscal 2025 it spent $783M on research and development and $106M on advertising.

What does Jazz Pharmaceuticals's advertising figure include?

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Company and source

Filing
10-K for FY2025, filed Feb 24, 2026
Accession number
0001232524-26-000013
Company
Jazz Pharmaceuticals plc, CIK 1232524, SIC 2834 (Pharmaceutical Preparations)
Headquarters
Dublin
Incorporated in
L2
Fiscal year ends
December 31
Listed on
Nasdaq
SEC filer status
Large accelerated filer
Data
SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
Cite
Jazz Pharmaceuticals advertising spend, FY2009-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 24, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/jazz-pharmaceuticals/advertising-spend/
Download
CSV, all years · CSV, all 458 companies